GoAI
Get started
GRAIL Inc. logo

GRAIL Inc.

GRAL

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Regular session

$77.88

−$1.66 · -2.09%

Aug 24, 12:28 PM ET

GRAL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

53

Fair Value

Momentum

51

Neutral

Sentiment

38

Bearish

Risk resilience

20

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Joshua J. Ofman
Listed since
Jun 12, 2024
Employees
910

Market position

Day range

Current $77.88

52-week range

Current $77.88

Open
$81.87
Previous close
$79.54
Volume
142.08K
0.21× average
Average volume
682.37K
Average daily volume
Market cap
3.34B USD
Beta
3.25
Market reference 1
50-day average
$68.7502
+13.28% above average
200-day average
$73.3048
+6.24% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.99B USD
P/E (TTM)
-7.99×
P/B (TTM)
1.32×
P/S (TTM)
20.22×
EV / EBITDA
-7.92×
Earnings yield
-12.98%
Free cash flow yield
-9.51%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-10.83%
Operating margin
-338.40%
Net margin
-236.95%
Return on equity
-15.84%
Return on assets
-13.97%
Return on invested capital
-14.30%

Financial health

Debt / equity
0.04×
Current ratio
11.97×
Altman Z-score
1.47
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends933%-2969%-6871%-10774%Gross margin, FY2021: -684.39%Gross margin, FY2022: -209.63%Gross margin, FY2023: -102.69%Gross margin, FY2024: -62.12%Gross margin, FY2025: -42.52%Operating margin, FY2021: -8659.61%Operating margin, FY2022: -9798.18%Operating margin, FY2023: -1627.61%Operating margin, FY2024: -1743.03%Operating margin, FY2025: -362.95%Net margin, FY2021: -8539.39%Net margin, FY2022: -9719.35%Net margin, FY2023: -1574.23%Net margin, FY2024: -1613.92%Net margin, FY2025: -277.47%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -684.39%. Gross margin FY2022 -209.63%. Gross margin FY2023 -102.69%. Gross margin FY2024 -62.12%. Gross margin FY2025 -42.52%. Operating margin FY2021 -8659.61%. Operating margin FY2022 -9798.18%. Operating margin FY2023 -1627.61%. Operating margin FY2024 -1743.03%. Operating margin FY2025 -362.95%. Net margin FY2021 -8539.39%. Net margin FY2022 -9719.35%. Net margin FY2023 -1574.23%. Net margin FY2024 -1613.92%. Net margin FY2025 -277.47%.

Income trends

Revenue

147.17M USD+17.18%

Operating income

−534.16M USD+75.60%

Net income

−408.35M USD+79.85%
Income trends across reported periods706.18M USD−1.53B USD−3.77B USD−6B USDRevenue, FY2021: 14.61M USDRevenue, FY2022: 55.55M USDRevenue, FY2023: 93.11M USDRevenue, FY2024: 125.6M USDRevenue, FY2025: 147.17M USDOperating income, FY2021: −1.27B USDOperating income, FY2022: −5.44B USDOperating income, FY2023: −1.52B USDOperating income, FY2024: −2.19B USDOperating income, FY2025: −534.16M USDNet income, FY2021: −1.25B USDNet income, FY2022: −5.4B USDNet income, FY2023: −1.47B USDNet income, FY2024: −2.03B USDNet income, FY2025: −408.35M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 14.61M USD. Revenue FY2022 55.55M USD. Revenue FY2023 93.11M USD. Revenue FY2024 125.6M USD. Revenue FY2025 147.17M USD. Operating income FY2021 −1.27B USD. Operating income FY2022 −5.44B USD. Operating income FY2023 −1.52B USD. Operating income FY2024 −2.19B USD. Operating income FY2025 −534.16M USD. Net income FY2021 −1.25B USD. Net income FY2022 −5.4B USD. Net income FY2023 −1.47B USD. Net income FY2024 −2.03B USD. Net income FY2025 −408.35M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue147.17M USD125.6M USD93.11M USD55.55M USD14.61M USD
Cost of goods sold209.75M USD203.62M USD188.72M USD172M USD114.62M USD
Gross profit−62.57M USD−78.02M USD−95.61M USD−116.45M USD−100M USD
Research and development195.79M USD322.38M USD338.75M USD329.58M USD460.21M USD
Selling, general, and administrative275.8M USD367.82M USD362.56M USD296.44M USD234.06M USD
Operating expenses471.59M USD2.11B USD1.42B USD5.33B USD1.17B USD
Interest income28.65M USD26.73M USD7.95M USD1.74M USD332K USD
Depreciation and amortization156.34M USD158.06M USD158.7M USD154.76M USD58.45M USD
Operating income−534.16M USD−2.19B USD−1.52B USD−5.44B USD−1.27B USD
Net income−408.35M USD−2.03B USD−1.47B USD−5.4B USD−1.25B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
88%
7 beats, 1 miss, 0 met estimates
Average EPS surprise
+21.17%
8 comparable reports
Latest EPS result
-2.56
Estimate -2.66 · Beat by 3.76%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-2.11-2.94-3.76-4.59Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual -2.89, estimate -4.41, surprise +34.47%, Beat. Q2 2025, reported May 13, 2025: actual -3.1, estimate -4.03, surprise +23.08%, Beat. Q3 2025, reported Aug 12, 2025: actual -3.18, estimate -3.14, surprise -1.27%, Miss. Q4 2025, reported Nov 12, 2025: actual -2.46, estimate -3.36, surprise +26.79%, Beat. Q1 2026, reported Feb 19, 2026: actual -2.44, estimate -3.33, surprise +26.73%, Beat. Q2 2026, reported May 5, 2026: actual -2.29, estimate -2.76, surprise +17.11%, Beat. Q3 2026, reported Aug 5, 2026: actual -2.56, estimate -2.66, surprise +3.76%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -2.6, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates46.47M41M35.52M30.05MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 38.25M USD, estimate 34.4M USD, surprise +11.20%, Beat. Q2 2025, reported May 13, 2025: actual 31.84M USD, estimate 35.2M USD, surprise -9.55%, Miss. Q3 2025, reported Aug 12, 2025: actual 35.54M USD, estimate 34.1M USD, surprise +4.23%, Beat. Q4 2025, reported Nov 12, 2025: actual 36.19M USD, estimate 34.6M USD, surprise +4.61%, Beat. Q1 2026, reported Feb 19, 2026: actual 43.6M USD, estimate 43.58M USD, surprise +0.04%, Beat. Q2 2026, reported May 5, 2026: actual 40.79M USD, estimate 39.16M USD, surprise +4.16%, Beat. Q3 2026, reported Aug 5, 2026: actual 44.69M USD, estimate 42.39M USD, surprise +5.42%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate 44.32M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$62.75

19.43% downside
Past 12 months12-month forecastHigh $70.00Average $62.75Low $56.00

Rating distribution

7 ratings
Strong buy00%
Buy457%
Hold343%
Sell00%
Strong sell00%

Recent analyst actions

7 institutions
MizuhomaintainNeutral
TD CowenmaintainBuy
Piper SandlermaintainNeutral
BairdmaintainOutperform

GRAL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.73

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.43

-0.47%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.21

+0.03%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.96

-0.49%

Sanofi logo

SNY

Sanofi

$45.6371

-0.46%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$824.47

-1.15%

ETFs holding GRAL

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
117.11M
Weight
1.03%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$164.17-0.94%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
84.59M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.72-0.14%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
83.74M
Weight
0.10%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.41-0.52%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
30.78M
Weight
0.21%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.24-0.25%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
25.71M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.78-0.71%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
23.48M
Weight
0.22%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$211.99-0.74%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
15.89M
Weight
0.09%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.65-0.50%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
12.4M
Weight
0.05%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.52-0.90%

Continue in GoAI

Research GRAL

research.disclaimer